Literature DB >> 17078964

Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning.

Mei-Yun Zhang1, Vidita Choudhry, Igor A Sidorov, Vladimir Tenev, Bang K Vu, Anil Choudhary, Hong Lu, Gabriela M Stiegler, Hermann W D Katinger, Shibo Jiang, Christopher C Broder, Dimiter S Dimitrov.   

Abstract

The HIV envelope glycoprotein (Env) is composed of two non-covalently associated subunits: gp120 and gp41. Panning of phage-displayed antibody libraries against Env-based antigens has resulted mostly in selection of anti-gp120 antibodies. Native gp41 in the absence of gp120 is unstable. The use of gp41 fragments as antigens has resulted in selection of antibodies with only relatively modest neutralizing activity. To enhance selection of antibodies specific for gp41 in the context of the whole Env we developed a methodology termed competitive antigen panning (CAP). Using CAP, we identified a novel gp41-specific human monoclonal antibody (hmAb), m48, from an immune library derived from long-term nonprogressors with high titers of broadly cross-reactive neutralizing antibodies (bcnAbs). Selection of m48 was only successful using CAP and not through the conventional pre-incubation methodology. In assays based on spreading infection in peripheral blood mononuclear cells (PBMCs) m48 neutralized a panel of HIV-1 primary isolates from different clades more potently than the well-characterized broadly cross-reactive HIV-1-neutralizing antibodies IgG1 4E10 and Fab Z13. These results may have implications for the selection of novel gp41-specific bcnAbs and other antibodies, and for the development of HIV-1 inhibitors and vaccine immunogens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17078964      PMCID: PMC1805821          DOI: 10.1016/j.jim.2006.09.016

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  39 in total

1.  Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library.

Authors:  Mei-Yun Zhang; Yuuei Shu; Sanjay Phogat; Xiaodong Xiao; Fatim Cham; Peter Bouma; Anil Choudhary; Yan-Ru Feng; Inaki Sanz; Susanna Rybak; Christopher C Broder; Gerald V Quinnan; Thomas Evans; Dimiter S Dimitrov
Journal:  J Immunol Methods       Date:  2003-12       Impact factor: 2.303

2.  Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades.

Authors:  Mei-Yun Zhang; Yuuei Shu; Igor Sidorov; Dimiter S Dimitrov
Journal:  Antiviral Res       Date:  2004-03       Impact factor: 5.970

3.  Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41.

Authors:  John M Louis; Carole A Bewley; Elena Gustchina; Annie Aniana; G Marius Clore
Journal:  J Mol Biol       Date:  2005-09-30       Impact factor: 5.469

4.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

5.  Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1.

Authors:  Peter Bouma; Maria Leavitt; Peng Fei Zhang; Igor A Sidorov; Dimiter S Dimitrov; Gerald V Quinnan
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

6.  Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.

Authors:  Mei-Yun Zhang; Xiaodong Xiao; Igor A Sidorov; Vidita Choudhry; Fatim Cham; Peng Fei Zhang; Peter Bouma; Michael Zwick; Anil Choudhary; David C Montefiori; Christopher C Broder; Dennis R Burton; Gerald V Quinnan; Dimiter S Dimitrov
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

7.  XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41.

Authors:  Qian Zhao; Justin T Ernst; Andrew D Hamilton; Asim K Debnath; Shibo Jiang
Journal:  AIDS Res Hum Retroviruses       Date:  2002-09-20       Impact factor: 2.205

Review 8.  Prospects for an AIDS vaccine: three big questions, no easy answers.

Authors:  David A Garber; Guido Silvestri; Mark B Feinberg
Journal:  Lancet Infect Dis       Date:  2004-07       Impact factor: 25.071

Review 9.  Identifying epitopes of HIV-1 that induce protective antibodies.

Authors:  Susan Zolla-Pazner
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

Review 10.  Virus entry: molecular mechanisms and biomedical applications.

Authors:  Dimiter S Dimitrov
Journal:  Nat Rev Microbiol       Date:  2004-02       Impact factor: 60.633

View more
  21 in total

1.  Therapeutic antibodies, vaccines and antibodyomes.

Authors:  Dimiter S Dimitrov
Journal:  MAbs       Date:  2010-05-14       Impact factor: 5.857

2.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

3.  Highly efficient selection of epitope specific antibody through competitive yeast display library sorting.

Authors:  Vinita Puri; Emily Streaker; Ponraj Prabakaran; Zhongyu Zhu; Dimiter S Dimitrov
Journal:  MAbs       Date:  2013-05-29       Impact factor: 5.857

4.  Identification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor.

Authors:  Yun Zhu; Lu Lu; Liling Xu; Hengwen Yang; Shibo Jiang; Ying-Hua Chen
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 5.  Monoclonal antibody-based candidate therapeutics against HIV type 1.

Authors:  Weizao Chen; Dimiter S Dimitrov
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-23       Impact factor: 2.205

6.  Impaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice.

Authors:  Eduardo Lujan; Rolando Pajon; Dan M Granoff
Journal:  Infect Immun       Date:  2015-11-23       Impact factor: 3.441

7.  Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen.

Authors:  Mei-Yun Zhang; Yanping Wang; Marie K Mankowski; Roger G Ptak; Dimiter S Dimitrov
Journal:  Vaccine       Date:  2008-12-10       Impact factor: 3.641

8.  Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.

Authors:  Mei-Yun Zhang; Bang K Vu; Anil Choudhary; Hong Lu; Michael Humbert; Helena Ong; Munir Alam; Ruth M Ruprecht; Gerald Quinnan; Shibo Jiang; David C Montefiori; John R Mascola; Christopher C Broder; Barton F Haynes; Dimiter S Dimitrov
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

9.  Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.

Authors:  Josh D Nelson; Heather Kinkead; Florence M Brunel; Dan Leaman; Richard Jensen; John M Louis; Toshiaki Maruyama; Carole A Bewley; Katherine Bowdish; G Marius Clore; Philip E Dawson; Shana Frederickson; Rose G Mage; Douglas D Richman; Dennis R Burton; Michael B Zwick
Journal:  Virology       Date:  2008-05-21       Impact factor: 3.616

10.  Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.

Authors:  Xiaodong Xiao; Weizao Chen; Yang Feng; Zhongyu Zhu; Ponraj Prabakaran; Yanping Wang; Mei-Yun Zhang; Nancy S Longo; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2009-09-11       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.